About:
Cerberus Therapeutics, based in Boston, Massachusetts, uses alpaca-derived nanobodies to develop autoimmune and infectious disease therapies. Novalia Pishesha, Hidde Ploegh, and Harvey Lodish founded Cerberus Therapeutics in 2021. Their nanobody-based platforms drive the development of durable, potent, and protective immune responses.